- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.05. | Belite Bio auf dem Stifel Forum: Strategische Arzneimittelentwicklungen | 1 | Investing.com Deutsch | ||
| 22.05. | Belite Bio-Aktie hält 80 US-Dollar-Kursziel nach FDA-Durchbruchsstatus | 1 | Investing.com Deutsch | ||
| 22.05. | Belite Bio stock holds $80 target on FDA breakthrough nod | 3 | Investing.com | ||
| BELITE BIO Aktie jetzt für 0€ handeln | |||||
| 21.05. | Belite Bio gets FDA breakthrough therapy status for Stargardt disease treatment | 1 | Seeking Alpha | ||
| 21.05. | BELITE BIO, INC - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 21.05. | Belite Bio Reports Breakthrough Therapy Designation For Tinlarebant | 1 | RTTNews | ||
| 21.05. | Belite Bio, Inc: Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease | 198 | GlobeNewswire (Europe) | Designation is based on the pivotal Phase 3 DRAGON trial interim analysis results demonstrating Tinlarebant's efficacy and favorable safety profileTrial completion expected by Q4 2025 (including a... ► Artikel lesen | |
| 15.05. | Benchmark maintains Buy on Belite Bio stock, $80 price target unchanged | 1 | Investing.com | ||
| 15.05. | Belite Bio stock retains Overweight rating at Cantor Fitzgerald | 1 | Investing.com | ||
| 15.05. | Belite Bio signals positive DSMB review and targets 500-patient PHOENIX trial enrollment completion in Q3 2025 while maintaining strong cash runway | 5 | Seeking Alpha | ||
| 14.05. | Belite Bio GAAP EPS of -$0.27 beats by $0.08 | 1 | Seeking Alpha | ||
| 14.05. | BELITE BIO, INC - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 14.05. | Belite Bio, Inc: Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update | 88 | GlobeNewswire (Europe) | Following a pre-specified interim analysis, an independent Data Safety Monitoring Board (DSMB) recommended the pivotal Phase 3 trial (DRAGON) of Tinlarebant in adolescent Stargardt disease (STGD1)... ► Artikel lesen | |
| 29.04. | Belite Bio, Inc: Belite Bio Announces Poster Presentations at the Association for Research in Vision and Ophthalmology 2025 Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 15.04. | BELITE BIO, INC - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 26.03. | Belite Bio stock target raised to $80 at Benchmark | 1 | Investing.com | ||
| 21.03. | BELITE BIO, INC - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 18.03. | Belite Bio Analysts See Potential For Stock Gains With Progress In Key Trials | 2 | Benzinga.com | ||
| 18.03. | Belite Bio stock holds $100 target post-results | 1 | Investing.com | ||
| 17.03. | Belite Bio GAAP EPS of -$0.32 misses by $0.01 | 1 | Seeking Alpha |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANGAMO THERAPEUTICS | 0,461 | -0,67 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease | STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA)... ► Artikel lesen | |
| ARGENX | 487,20 | +1,84 % | EC approves argenx's subcutaneous Vyvgart for rare autoimmune disease CIPD | ||
| AVID BIOSERVICES | 12,100 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 05.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 05.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 05.02.2025ISIN NameCA75525M1095 RAZOR... ► Artikel lesen | |
| PROTALIX BIOTHERAPEUTICS | 1,290 | -4,44 % | Protalix BioTherapeutics, Inc. - 8-K, Current Report | ||
| ENZO BIOCHEM | 0,570 | +7,55 % | Enzo Biochem, Inc. To be Acquired by Battery Ventures in All-Cash Transaction | Transaction Follows Completion of Comprehensive Strategic Review by Special Committee of the Board to Maximize Shareholder Value Farmingdale, NY, June 24, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc.... ► Artikel lesen | |
| QUANTERIX | 6,660 | +1,37 % | Quanterix's Simoa analyzer gains medical device registration in S.Korea | ||
| LEXEO THERAPEUTICS | 4,120 | -1,44 % | Lexeo to help launch spinout around RNA drugs for the heart | ||
| SOLID BIOSCIENCES | 4,720 | -1,87 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung | ||
| HARMONY BIOSCIENCES | 31,980 | +0,38 % | Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data | ||
| CG ONCOLOGY | 25,950 | -0,46 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
| QIAGEN | 41,000 | -0,56 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
| LYELL IMMUNOPHARMA | 8,940 | -1,97 % | Lyell Immunopharma, Inc. - 8-K, Current Report | ||
| SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc. - 8-K, Current Report | ||
| KYMERA THERAPEUTICS | 44,080 | -3,57 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
| CLIMB BIO | 1,180 | -5,60 % | Climb Bio, Inc.: Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer | Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll... ► Artikel lesen |
BELITE BIO INC ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -0,40 % bei einem Aktienkurs von 49,800 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BELITE BIO INC ADR finden Sie auf Wallstreet Online.